Nifty Pharma advances 150 pts; Divis Labs emerges top bull; Cadila, Dr Reddys add to winnings

Share
AuthorPosted at
Recently, Special Expert Committee approved Bharat Biotech's Phase 3 trials efficacy data for Covaxin. It is 77.8%.

from India Infoline News Service https://ift.tt/2UK8GRf
Post a Comment
Labels

Comments